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LETTER TO THE EDITORIntravesicular Cidofovir for
the Management of BK Virus-
Associated Cystitis
Hemorrhagic cystitis (HC) is a complication of
hematopoietic stem cell transplantation (SCT), occur-
ring in 10% to 70% of transplant recipients [1]. Inten-
sive preparative regimens, especially those including
busulfan, high-dose cyclophosphamide or ifosfamide,
allogeneic SCT, transplantation from unrelated
donors, and graft-versus-host disease (GVHD) are all
factors that may contribute to the development of
HC [2-4].
The frequent finding of BK viral particles in the
urine of patients with postengraftment HC also impli-
cates this agent in the pathogenesis of postengraft-
ment HC [4,5]. BK virus (BKV) is a human
polyomavirus, a nonenveloped virus with circular,
double-stranded DNA. Approximately 80% of adults
are seropositive, as exposure to BKV commonly
occurs in early childhood. The reactivation of latent
BKV in the kidney is thought to lead to the develop-
ment of late-onset HC in hematopoietic stem cell
transplant patients, most commonly within the first
2 months after transplant.
Prophylaxis and treatment of BKV-associated
cystitis has been attempted with agents such as mesna,
quinolones, leflunomide, and the use of hyperhydra-
tion or bladder irrigation; however, none are particu-
larly effective in treating the viruria or in diminishing
cystitis-related symptoms. Cidofovir (CDF) has been
shown to have both in vitro and in vivo antiviral
activity against polyomaviruses [6,7]. Reports of
intravenous CDF’s efficacy in BKV-associated HC
were associated with excessive toxicity, especially renal
insufficiency. Intravesicular installation of CDF was
first reported in 2005 for the management of adenovi-
rus associated HC [1]. In this report we describe our
favorable experience with the use of intravesicular
CDF for the treatment of BKV-associated HC.
Patients were initiated on treatment with intrave-
sicular CDF if, in addition to BK viruria, they experi-
enced hematuria, dysuria, or urinary urgency. A dose
of 5 mg/kg body weight was diluted in a 60-mL
syringe with 0.9% sodium chloride and instilled into
the bladder via a Foley catheter. If the patient had an
indwelling catheter, the catheter was clamped follow-
ing instillation of CDF for 1 hour to facilitate expo-
sure of drug to the bladder wall. This was repeated
daily for 2 days if the catheter remained in place. In
patients without need of an indwelling catheter, theFoley catheter was removed immediately after drug
instillation and patients were permitted to urinate as
needed. Doses were repeated weekly until resolution
of symptoms.
A total of 6 patients, 5 matched unrelated donor
(MUD), 1 matched related donor (MRD), have been
treated thus far. All were recipients of allogeneic
SCTs, and presented with symptoms of cystitis while
having detectable levels of BKV in the urine. Symp-
toms included dysuria in 1, urinary urgency in 2, and
hematuria in 3 patients. Following initiation of CDF
therapy, all 6 patients experienced resolution of their
cystitis symptoms. Two patients had resolution of
symptoms with a single dose, whereas 3 had resolution
of symptoms after 2 weekly doses. Urine BK viral loads
were measured in 4 patients, and the response was
variable; 3 had decreases in viral loads, whereas 1 had
a marked increase despite resolution of symptoms.
None of the patients developed renal toxicities attrib-
utable to CDF therapy, and other than mild reports of
pain associated with the instillation and retention of
the product in the bladder, the treatment was well
tolerated.
In summary, this report summarizes our favorable
experience with the first series of patients treated
with intravesicular CDF for BKV-associated HC.
Treatment was generally well tolerated, and appears
to hold potential for the symptomatic improvement
of cystitis.REFERENCES
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